Voyager Therapeutics (NASDAQ:VYGR) Releases Earnings Results

Voyager Therapeutics (NASDAQ:VYGR) issued its earnings results on Thursday. The company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.01, FiscalAI reports. Voyager Therapeutics had a negative return on equity of 57.92% and a negative net margin of 312.63%. The firm had revenue of $0.61 million for the quarter, compared to the consensus estimate of $6.35 million.

Voyager Therapeutics Stock Performance

Shares of VYGR traded up $0.14 during trading hours on Friday, reaching $1.86. The stock had a trading volume of 870,782 shares, compared to its average volume of 999,618. Voyager Therapeutics has a 12 month low of $1.68 and a 12 month high of $5.48. The stock has a market capitalization of $114.92 million, a PE ratio of -1.08 and a beta of 1.20. The company’s 50-day moving average is $2.55 and its two-hundred day moving average is $3.41.

Wall Street Analyst Weigh In

Several research firms recently weighed in on VYGR. Wall Street Zen lowered Voyager Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday. HC Wainwright reissued a “buy” rating on shares of Voyager Therapeutics in a research note on Thursday, August 27th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Voyager Therapeutics in a report on Friday, October 9th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $16.50.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a biotechnology company focused on developing gene therapies for neurological diseases. The company aims to address conditions affecting the central nervous system by using adeno-associated virus (AAV) gene-delivery technologies to deliver therapeutic genes to targeted areas of the brain and nervous system.

Voyager’s research platform, known as TRACER, is designed to identify AAV capsids with improved ability to cross the blood-brain barrier and reach the central nervous system.